Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and InfantsActive Not Recruiting
NCT06647407Phase 1, Phase 2Updated Jan 20, 2026
Sponsor: Sanofi Pasteur, a Sanofi Company
Meningococcal Immunization · Healthy Volunteers
Brazil, Czechia, Denmark, Finland, Germany +4 more
Goal Attainment and Physical Activity in People With Hemophilia ATerminated
NCT06530030N/AUpdated Jan 20, 2026
Sponsor: Sanofi
Hemophilia A
United States
Comprehensive Assessment of Neurodegeneration and DementiaRecruiting
NCT03402919N/AUpdated Jan 20, 2026
Sponsor: McGill University
Dementia · Mild Cognitive Impairment (MCI) · Subjective Cognitive Impairment · Parkinson's Disease (PD)
Canada
A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.Completed
NCT06850051Phase 1Updated Jan 16, 2026
Sponsor: Sanofi
Healthy Volunteers · Influenza Vaccination · Respiratory Syncytial Virus Vaccination · Parainfluenza Vaccination
Australia
Avalglucosidase Alfa Pregnancy StudyRecruiting
NCT05734521N/AUpdated Jan 16, 2026
Sponsor: Sanofi
Pompe Disease · Pregnancy
United States
Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and OlderActive Not Recruiting
NCT06907511Phase 1, Phase 2Updated Jan 16, 2026
Sponsor: Sanofi
Pandemic Influenza Immunization · Healthy Volunteers
United States
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo NodularisRecruiting
NCT06293053Phase 3Updated Jan 15, 2026
Sponsor: Sanofi
Prurigo Nodularis
United States
The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant RecipientsEnrolling By Invitation
NCT03292861Phase 2Updated Jan 14, 2026
Sponsor: Cedars-Sinai Medical Center
Heart Transplantation
United States
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple MyelomaRecruiting
NCT05922501Phase 2Updated Jan 14, 2026
Sponsor: Massachusetts General Hospital
Relapsed Cancer · Refractory Multiple Myeloma · Multiple Myeloma
United States
Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid TumorsTerminated
NCT05450562Phase 1, Phase 2Updated Jan 14, 2026
Sponsor: Sanofi
Neoplasm
United States, Canada, China, Singapore, South Korea
Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and AdolescentsCompleted
NCT06128733Phase 1, Phase 2Updated Jan 13, 2026
Sponsor: Sanofi Pasteur, a Sanofi Company
Meningococcal Immunisation · Healthy Volunteers
United States, Puerto Rico
A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1BActive Not Recruiting
NCT02065011Phase 2Updated Jan 13, 2026
Sponsor: Sanofi
Usher's Syndrome
United States, France
A First-in-human Study to Investigate Safety and Tolerability of SAR446959 in Participants With Osteoarthritis of the KneeCompleted
NCT06704932Phase 1Updated Jan 12, 2026
Sponsor: Sanofi
Osteoarthritis
Germany
Glucose Consumption in MS Using [F-18]FDG-PETRecruiting
NCT07087106Phase 4Updated Jan 9, 2026
Sponsor: Brigham and Women's Hospital
Multiple Sclerosis
United States
IL-13 Blockade and Airway Autoimmunity in AsthmaCompleted
NCT05564078N/AUpdated Jan 9, 2026
Sponsor: McMaster University
Airway Auto Immunity in Asthma
Canada
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)Completed
NCT04458051Phase 3Updated Jan 7, 2026
Sponsor: Sanofi
Primary Progressive Multiple Sclerosis
United States, Argentina, Australia, Austria, Belarus +37 more
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard TherapiesCompleted
NCT05054725Phase 2Updated Jan 6, 2026
Sponsor: Revolution Medicines, Inc.
Non-Small Cell Lung Cancer
United States, Australia, Canada, France, Germany +5 more
Impact of FLU Vaccination on Nasal Resident Memory Immune Responses and Peripheral Respiratory-tropic Memory Immune ResponsesActive Not Recruiting
NCT06824779Phase 4Updated Dec 30, 2025
Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Volunteers · Flu Vaccine
France
Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic PurpuraCompleted
NCT05468320Phase 3Updated Dec 30, 2025
Sponsor: Sanofi
Thrombotic Thrombocytopenic Purpura
United States, Belgium, Canada, Czechia, France +6 more
Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)Active Not Recruiting
NCT03428646N/AUpdated Dec 29, 2025
Sponsor: Regeneron Pharmaceuticals
Dermatitis, Atopic
United States, Canada
A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple MyelomaActive Not Recruiting
NCT05704049Phase 2Updated Dec 29, 2025
Sponsor: Sanofi
Relapsed/Refractory Multiple Myeloma
Australia, Brazil, China, Czechia, Greece +2 more
A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]Terminated
NCT05179603Phase 2Updated Dec 24, 2025
Sponsor: Sanofi
Classic Hodgkin Lymphoma · Diffuse Large B-cell Lymphoma
Argentina, Chile, Spain
Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of AgeTerminated
NCT04544267Phase 3Updated Dec 24, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza
United States
A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)Active Not Recruiting
NCT06101095Phase 4Updated Dec 23, 2025
Sponsor: Sanofi
Eosinophilic Oesophagitis
United States, Brazil, Canada, Israel, Switzerland
Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell CarcinomaCompleted
NCT04154943Phase 2Updated Dec 23, 2025
Sponsor: Regeneron Pharmaceuticals
Cutaneous Squamous Cell Carcinoma
United States, Australia, Germany

Previous page Next page